Back to results
US 5,710,174 AGranted
Factor XIIIA inhibitor
AssigneesZymo Genetics, Inc., Novo Nordisk A/S
InventorsRobert R. West, Teresa Martinez, Hank R. Franklin, Paul D. Bishop, Birgitte R.o slashed.mer Rassing
Life of this patent
Estimating the term…
Abstract
A compound that is useful for inhibiting FXIIIa catalysis of fibrin cross-linking, and related pharmaceutical compositions and methods, are disclosed. The compound and compositions may be advantageously used to enhance fibrinolysis and resolution of blood clots.
Claims9
A pharmaceutical composition comprising a compound having the structure:
- ##STR2## a buffer, and a pharmaceutically acceptable vehicle.
A pharmaceutical composition comprising a compound having the structure:
- ##STR3## a pharmaceutically acceptable vehicle, and a fibrinolytic agent.
A method for inhibiting FXIIIa catalysis of fibrin cross-linking in vivo comprising:
- administering to a recipient a therapeutic amount of a pharmaceutical composition comprising a compound having the structure:
- ##STR4## and a pharmaceutically acceptable vehicle, in an amount sufficient to inhibit FXIIIa catalysis of fibrin cross-linking.
Dependencies are inferred from the claim text.